Skip to main content
Premium Trial:

Request an Annual Quote

OpGen Raises $2.1M in Financing

NEW YORK (GenomeWeb News) – OpGen has raised $2.1 million, the Gaithersburg, Md., firm confirmed today.

The raise, which OpGen disclosed in a document filed with the US Securities and Exchange Commission on Friday, is bridge financing and will be used to support the commercialization of its flagship technology, the Argus Optical Mapping System, a company spokesman told GenomeWeb Daily News today.

The platform was launched last year. In its filing, the company said it is targeting $2.3 million in the round.

OpGen's platform uses optical mapping technology for whole-genome sequence assembly and finishing. The company, founded in 2002, is seeking to commercialize products and services based on its technologies "for high-precision microbial analysis as well as human, animal, and plant genome sequencing," the spokesman said.

There were 27 participants in the round, including "significant" existing investors.

The molecular diagnostics firm raised $20 million in a Series B round earlier this year.

The Scan

Push Toward Approval

The Wall Street Journal reports the US Food and Drug Administration is under pressure to grant full approval to SARS-CoV-2 vaccines.

Deer Exposure

About 40 percent of deer in a handful of US states carry antibodies to SARS-CoV-2, according to Nature News.

Millions But Not Enough

NPR reports the US is set to send 110 million SARS-CoV-2 vaccine doses abroad, but that billions are needed.

PNAS Papers on CRISPR-Edited Cancer Models, Multiple Sclerosis Neuroinflammation, Parasitic Wasps

In PNAS this week: gene-editing approach for developing cancer models, role of extracellular proteins in multiple sclerosis, and more.